Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 19/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368999 | 1.00 | CCR3 (0.43) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14369124 | 1.00 | CCR3 (0.43) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14394453 | 0.93 | CCR3 (0.45) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL14368666 | 0.92 | CCR3 (0.45) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4435281 | 0.89 | CCR3 (0.46) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4435643 | 0.89 | CCR3 (0.46) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4553275 | 0.89 | CCR3 (0.46) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4552768 | 0.88 | CCR3 (0.47) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL5662391 | 0.87 | CCR3 (0.46) | CCR3CYP2D6DRD2SLC6A2HTR2A | |
| SCHEMBL4435352 | 0.87 | CCR3 (0.45) | CCR3CYP2D6DRD2SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101484442-A | Compounds that are agonists of muscarinic receptors and tha may be effective in treating pain, alzheimer's disease and/or schizophrenia | ASTRAZENECA AB (SE) | 2009-07-15 | — | — | CN | disclosed |